Skip to main navigation
Madrigal Pharmaceuticals Madrigal Pharmaceuticals.
  • About Us
    • Overview
    • Leadership
    • Board Of Directors
  • Our Programs
    • Overview
    • Resmetirom
      • Clinical Trials
      • Publications
  • NASH
    • Overview
    • Patient and HCP Perspectives
    • Resources
  • Investors & Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Financials and Filings
    • Stock Information
    • Corporate Governance
    • FAQs
    • Email Alerts
  • Careers
    • Join the team
  • Contact
    • General Inquires
    • Medical Information Inquiries
    • Medical Education Grant Submissions
Search
  • About Us
    • Overview
    • Leadership
    • Board Of Directors
  • Our Programs
    • Overview
    • Resmetirom
      • Clinical Trials
      • Publications
  • NASH
    • Overview
    • Patient and HCP Perspectives
    • Resources
  • Investors & Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Financials and Filings
    • Stock Information
    • Corporate Governance
    • FAQs
    • Email Alerts
  • Careers
    • Join the team
  • Contact
    • General Inquires
    • Medical Information Inquiries
    • Medical Education Grant Submissions
  • Overview
  • Press Releases
  • Events and Presentations
  • Financials and Filings
  • Stock Information
  • Corporate Governance
  • FAQs
  • Email Alerts

EASL Investor Event and Webcast

Jun 25, 2022 at 3:00 PM EDT

Click here for Webcast

We are conducting a late-stage clinical development program to demonstrate the benefit of resmetirom to patients with NASH and liver fibrosis.

Learn More
Madrigal Pharmaceuticals. Logo

Madrigal Pharmaceuticals

200 Barr Harbor Drive,
Suite 200

West Conshohocken,
Pennsylvania 19428

  • About Us
  • Our Programs
  • NASH
  • Investors & Media
  • Careers
  • Contact
Madrigal Pharmaceuticals
  • Terms of Use
  • Privacy
  • Cookies
  • CA COMPLIANCE
©2023 Madrigal Pharmaceuticals. All rights reserved.